Vicapsys Life Sciences (VICP) Stock Price, News & Analysis

Company Overview

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

Key Stats

• Today's Range: $1.77 to $1.77
• 50-Day Range: $1.25 to $3.00
• 52-Week Range: $1.25 to $3.00
• Volume: N/A
• Average Volume: 250 shs
• Market Capitalization: $57.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vicapsys Life Sciences Stock Analysis - MarketRank™

Vicapsys Life Sciences scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vicapsys Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vicapsys Life Sciences is -44.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vicapsys Life Sciences is -44.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Vicapsys Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Vicapsys Life Sciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vicapsys Life Sciences does not currently pay a dividend.

Dividend Growth

Vicapsys Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Vicapsys Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Vicapsys Life Sciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for VICP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vicapsys Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.98% of the stock of Vicapsys Life Sciences is held by insiders.

VICP Stock Analysis - Frequently Asked Questions

How have VICP shares performed this year?

Vicapsys Life Sciences' stock was trading at $1.50 at the beginning of the year. Since then, VICP shares have increased by 18.0% and is now trading at $1.77.
View the best growth stocks for 2025 here.

How were Vicapsys Life Sciences' earnings last quarter?

Vicapsys Life Sciences, Inc. (OTCMKTS:VICP) announced its quarterly earnings data on Friday, January, 10th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Vicapsys Life Sciences?

Shares of VICP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vicapsys Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vicapsys Life Sciences investors own include Vapotherm (VAPO), Reliance Global Group (RELI), NLS Pharmaceutics (NLSP), Meta Platforms (META), Fantex (EJMLL), Digital Transformation Opportunities (DTOCU) and Comtech Telecommunications (CMTL).

Company Calendar

• Last Earnings: 1/10/2025
• Today: 4/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Construction
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VICP
• CIK: 1468639
• Web: vicapsys.com
• Phone: (972) 891-8033
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,180,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -3,906.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.06) per share
• Price / Book: -29.50

Miscellaneous

• Outstanding Shares: 32,371,000
• Free Float: 30,435,000
• Market Cap: $57.30 million
• Optionable: Not Optionable
• Beta: -4.03